Navigation Links
Anti-clotting agent does not improve outcomes of patients with severe pneumonia
Date:2/22/2011

Use of the blood clot-inhibiting medication tifacogin does not appear to improve outcomes of patients with severe community-acquired pneumonia (sCAP), according to a study conducted by researchers from North and South America, Europe, Asia and Africa. The drug had shown some potential benefit in the sCAP subgroup of an earlier trial involving sepsis patients.

The findings were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

"Administration of tifacogin showed no treatment benefit in this large population of patients with severe CAP,"said Richard Wunderink, MD, professor of pulmonary and critical care medicine at Northwestern University's Feinberg School of Medicine. "This result was consistent across a range of disease severity indices."

In the U.S., community-acquired pneumonia (CAP) is the eighthleading cause of death, with a death rate of 18.8/100,000. The number of individuals hospitalized with CAP annually is expected to increase up to 1 million in 2020, with similar trends in many other countries due to the disproportionate growth of the elderly population. Globally, intensive care unit mortality in patients admitted with sCAP is about 30%.

In most sCAP patients, the blood clotting system is activated as part of the response to infection, in some cases interfering with circulation and leading to multiple organ failure. Researchers hope reducing this excess clottingthrough use of anticoagulants in individuals with sCAP may prevent organ failure.

Tifacoginacts by blocking activated tissue factor, an essential for clot formation. In aprior trial of sepsis patients, tifacogin had shown some benefit for patients in that trial who had CAP. Based on those results, Dr. Wunderink said researchers involved in this study, dubbed CAPTIVATE (Community-Acquired Pneumonia Tifacogin Intra-Venous Administration Trial for Efficacy), aimed to assess the efficacy and safety of tifacogin as adjunct therapy in sCAP.

"CAP remains the most common cause of death from infection," Dr. Wunderink said. "Anti-clotting therapies are sought to complement the antimicrobial treatment and supportive care measures that are currently used for sCAP patients."

In this study, researchers enrolled 2,138 sCAPpatients from 188 centers from 2005 to 2008, randomizing them to receive tifacogin or placebo intravenously for four days. Although two doses of tifacogin (0.025 mg/kg/h and 0.075 mg/kg/h) were initially included in the study, the higher dose was dropped early on when no benefit was demonstrated.

At the end of the study although tifacogin did show an effect on clotting measures in the blood, the researchers found mortality rates and the incidence of adverse events were similar in both the tifacogin and placebo groups.

Dr. Wunderink said the study's negative results could be due to several factors.

"The coagulation and inflammatory responses may have been irreversibly activated before tifacogin was administered, or specific processes that occur during CAP may have blunted the effect of the drug," he said. "However, the most logical explanation is that tissue factor activation, while important, may not be a critical step in the pathogenesis of sCAP mortality."

Although the study showed no benefit associated with the use of tifacogin in sCAP patients, Dr. Wunderink said it clearly demonstrates the need for additional research to improve sCAP mortality rates.

"CAPTIVATE represents the largest clinical trial of severe CAP performed to date," Dr. Wunderink said. "The design and execution of the study demonstrates that a more homogeneous population with a single source ofinfection, rather than a more generic sepsis population, can be defined, which will be of benefit for future studies.

"Although theprimary end-point was not achieved, this study demonstrates the persistent unmet need forfurther interventions to improve mortality of sCAP and the feasibility of those studies," he added.


'/>"/>

Contact: Brian Kell
bkell@thoracic.org
212-316-6442
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. New Anti-Clotting Drug May Work Better After Hip Replacement
2. Extended use of anti-clotting drug helps some bedridden patients
3. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
4. VCU Massey first to combine targeted agents to kill multiple myeloma cells
5. SNM applauds FDA advisory committee recommendation for approval of Alzheimers imaging agent
6. Study provides molecular rationale for combining targeted agents to treat breast cancer
7. Colorectal cancer patients with gene mutation show better response to cancer agent
8. Targeted agent shows promise for chronic lymphoid leukemia
9. Agent Orange exposure linked to Graves disease in Vietnam veterans, UB study finds
10. New Research Uncovers Elusive Target of Antifungal Agent
11. Compound enhances cancer-killing properties of agent in trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved walking one ... with one on her shoulder and one on her arm. But she got to ... years of mitral valve prolapse. , The valves of the heart wouldn’t close properly ...
(Date:5/3/2016)... Pasadena, CA (PRWEB) , ... May 03, 2016 ... ... tuition-free, accredited American online university, has announced today the launch of its Associates ... Nobel Laureate and President Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Boston Children’s Hospital ... rehearse tough medical situations or practice tricky or rare procedures in an environment that ... the SIM Center is also available to inventors and “hackers” to develop and test ...
(Date:5/3/2016)... ... 03, 2016 , ... Park Cities Pet Sitter has openings for both full-time ... 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. ... Plano, Preston Hollow and Park Cities areas of the Metroplex. Candidates must love ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 ... ... solutions for the healthcare industry, announced today that Legacy Health is expanding its ... Efficient Works platform), after a highly successful initial proof of concept. The Portland, ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... about the importance of extending care beyond the implant ... Scientific Sessions, May 4-7 in San Francisco ... tasked with continually delivering the highest quality of patient ... ensuring patients are cared for each and every tomorrow," ...
Breaking Medicine Technology: